We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
-1.43%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$395M
AUM Growth
-$219M
Cap. Flow
-$88.1M
Cap. Flow %
-22.29%
Top 10 Hldgs %
44.14%
Holding
133
New
27
Increased
24
Reduced
29
Closed
30

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$9.2M
2
CELG
Celgene Corp
CELG
+$7.8M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$5.42M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$5.26M
5
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$4.79M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$16.1M
2
LLY icon
Eli Lilly
LLY
+$16.1M
3
BIIB icon
Biogen
BIIB
+$15.7M
4
PFE icon
Pfizer
PFE
+$14.4M
5
AMGN icon
Amgen
AMGN
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 66.6%
2 Miscellaneous 19.06%
3 Technology 5.44%
4 Communication Services 2.79%
5 Industrials 1.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
101
DELISTED
Ignyta, Inc.
RXDX
$117K 0.03%
+22,065
New +$129K
ABUS icon
102
Arbutus Biopharma
ABUS
$1B
$54K 0.01%
22,000
-278,000
-93% -$809K
AAPL icon
103
CALL
Apple
AAPL
$4.92T
– –
-74,000
Closed -$2.76M
ACAD icon
104
Acadia Pharmaceuticals
ACAD
$4.71B
– –
-125,000
Closed -$3.98M
ACIU icon
105
AC Immune
ACIU
$267M
– –
-79,800
Closed -$1.31M
AMGN icon
106
Amgen
AMGN
$204B
– –
-65,900
Closed -$11M
ARWR icon
107
Arrowhead Research
ARWR
$9.57B
– –
-100,000
Closed -$735K
BIIB icon
108
Biogen
BIIB
$32.2B
– –
-50,000
Closed -$15.7M
BMRN icon
109
CALL
BioMarin Pharmaceuticals
BMRN
$12.6B
– –
-80,000
Closed -$7.4M
BURL icon
110
Burlington
BURL
$15B
– –
-18,500
Closed -$1.5M
ELLO icon
111
Ellomay Capital Ltd
ELLO
– –
-5,653
Closed -$51K
GILD icon
112
CALL
Gilead Sciences
GILD
$186B
– –
-39,200
Closed -$3.1M
GILD icon
113
Gilead Sciences
GILD
$186B
– –
-112,700
Closed -$8.92M
HSIC icon
114
Henry Schein
HSIC
$9.53B
– –
-2,550
Closed -$163K
LLY icon
115
Eli Lilly
LLY
$1.02T
– –
-200,000
Closed -$16.1M
ORA icon
116
Ormat Technologies
ORA
$5.97B
– –
-7,640
Closed -$370K
PFE icon
117
Pfizer
PFE
$158B
– –
-449,649
Closed -$14.4M
VTRS icon
118
Viatris
VTRS
$19.7B
– –
-200,000
Closed -$7.62M
ALIM
119
DELISTED
Alimera Sciences
ALIM
– –
-13,381
Closed -$299K
ALPN
120
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-51,175
Closed -$1.66M
KDNY
121
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-28,000
Closed -$1.74M
ACOR
122
DELISTED
Acorda Therapeutics
ACOR
– –
-1,233
Closed -$3.09M
ENDP
123
DELISTED
Endo International plc
ENDP
– –
-150,000
Closed -$3.02M
ADXS
124
DELISTED
Advaxis Inc
ADXS
– –
-13,333
Closed -$2.14M
TRIL
125
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-132,300
Closed -$1.96M
2 3 4
5
6

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sphera Funds Management held 133 positions worth $395M, down 36% from $614M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sphera Funds Management withdrew a net $88.1M in Q4 2016, closing 30 positions and reducing 29 holdings. Its most notable exit was Allergan plc, an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 62% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Sphera Funds Management opened a new position in BioMarin Pharmaceuticals worth $3.73M.

  • Sphera Funds Management's largest Q4 2016 buy was BioMarin Pharmaceuticals: 45,000 shares worth $3.73M.
  • Sphera Funds Management added most to Merck in Q4 2016, an estimated $9.2M increase.
  • Sphera Funds Management's biggest Q4 2016 reduction was Achaogen Inc, cutting an estimated $5.39M.
  • Sphera Funds Management fully exited Allergan plc in Q4 2016, selling an estimated $16.1M.
  • Sphera Funds Management's ten largest holdings make up 44% of its $395M portfolio in Q4 2016.
  • Sphera Funds Management opened 27 new positions and closed 30 in Q4 2016.
  • Sphera Funds Management's portfolio value fell 36% quarter-over-quarter to $395M.

Based on Sphera Funds Management's 13F filing for Q4 2016, filed 13 Feb 2017.